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ABSTRACT  
Hydroxychloroquine (HCQ) as a drug grabbed serious attention of whole world in dealing with COVID-19 pandemic. Recently some in-vitro and 
in-vivo study showing possible inhibition of SARS-CoV-2 by use of HCQ. However at the same time, some case studies showing NO clinical 
benefit/ poor clinical outcome with substantial detrimental adverse effects by use of HCQ in treatment of coronavirus disease-2019. Thus, the 
HCQ use (in COVID-19 treatment) is of current international interest, although a consensus has not yet been reached. More evidences are still 
required to prove efficacy of HCQ against COVID-19. In view of this, the present review highlights the current ongoing research related to use of 
HCQ in treatment coronavirus disease-2019. The present review will discuss the possible anti-viral mechanism of HCQ, prophylaxis strategy 
and effect of HCQ against SARS-CoV-2 virus in-vitro study. Further this review also summarizes and debates all available clinical trials/ case 
studies of HCQ use against COVID-19 (with clinical outcome). Finally possible detrimental adverse effects are also discussed considering the 
public health and pharmacovigilance concern. 
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1. Introduction: 
Year 2020 started with the novel coronavirus 2019 disease 
(COVID-19) which has been declared a pandemic [1]. It is 
third extremely pathogenic and contagious coronavirus after 
endemic SARS-CoV and MERS-CoV appeared in humans [2]. 
The exact origin, transmission, mechanisms of SARS-CoV-2 is 
not confirmed and clear until now, however, its genome 
sequence is closely correlated (76-80 %) with the SARS-CoV 
coronavirus [2]. As of now (25th April 2020), approximately 
29,01,305 patients have been confirmed to have COVID-19 
infection globally (212 countries) with 2,00,082 fatalities [3]. 
Development of potential therapy is urgently required in 
order to prevent pandemic COVID-19. On 30th March 2020, 
Food and Drug Administration of USA issued an Emergency 
Use Authorization of HCQ and chloroquine (CQ) for treatment 
of certain COVID-19 patients [4].  
A controversial anti-malaria drug being explored and used in 
random clinical trials and clinical case studies around the 
world against potential COVID-19 in order to get relieve from 
symptoms, or as a preventative measure to stop people being 
get infected with COVID-19 [5-10]. Some reports showing 
potential use of the HCQ in treatment of coronavirus disease-
2019 (with minimum side effects) [5,6,9]. At the same time 
some reports are NOT at all supporting potency of HCQ for 
COVID-19 [7,8,10], conversely they reported increase of 
adverse events by use of HCQ in COVID-19 patient [10]. Thus, 
there are several toxic effects of HCQ which are needed to 
address considering prophylaxis use in view of 
pharmacovigilance concern [7,8,10]. It may be toxic enough 
that many people may extensively suffer or may even die due 
to cardiac problem during the treatment [10]. Hence a very 
careful analysis is still needed for the use of HCQ in treatment 
of coronavirus disease-2019 [7,8,10]. Thus, the debate for use 
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of the HCQ against COVID-19 is of great attention which 
needs an urgent consideration in order to understand the 
actual potency of HCQ against COVID-19 [5-10]. 
The use of the HCQ medicine in treatment of coronavirus 
disease-2019 is of current international interest, although a 
consensus has not yet been reached which may ask for more 
powerful evidences. In view of this, the present review is 
done to highlight (i) the antiviral use of HCQ against various 
viruses, (ii) possible mode of action of HCQ against SARS-CoV-
2, (iii) in vitro-inhibition of SARS-CoV-2 virus by HCQ, (iv) 
conflicts in-vivo clinical trials/case studies explaining the 
therapeutic role of HCQ in coronavirus disease-2019 patient, 
(v) prophylactic use of HCQ (vi) side effects and 
pharamcovigilance concern of use of HCQ. 
2. 4-Aminoquinolines and their anti-viral 
therapeutics applications: 
Hydroxychloroquine and chloroquine are 4-aminoquinoline 
derivatives. The change in N-diethyl side chain of CQ by N-
ethyl hydroxyl group in HCQ offers more solubility. Further, 
HCQ showed significant bioavailability and 
immunomodulatory effects by interfering interleukin-6 
synthesis (IL-6) which has essential role in chronic 
inflammation and auto-immunity [11-13]. Furthermore, HCQ 
produces less toxic metabolites, less adverse effects and 
hence considered safer drug than CQ [11-14]. Besides this, 
HCQ also displayed anti-viral activity by stimulating the 
pathway of IFN-β via phosphorrylation [11,12]. HCQ is 
primarily an anti-malarial drug which is also used in 
autoimmune diseases [11-13], sarcoidosis [14], rheumatoid 
arthritis [15], alopecia areata [16], lupus erythematosus [17], 
anti-thrombotic [18] and antineoplastic treatment [19]. 
Moreover, HCQ shows potential antiviral activity and 
therapeutic use against Ebola [20], Marburg [20], Zika [21], 
HIV-1[22], Dengue [23], Chikunguniya [24], Hepatitis C [25], 
MERS-CoV [26] and SARS-CoV [27] virus treatment.  
Various pathways for mechanism of action of HCQ are 
explained against virus [20-27]. Haque et al., [20] proposed 
that, HCQ deposition in the endosome increases the pH and 
causes inactivation of lysosomal enzymes as well as 
receptors which inhibits entry of virus. Kumar et al. [21] 
reported that, HCQ activates the innate immune signal 
pathways and promote the production of reactive oxygen 
species which inhibit Zika virus cycle. Romanelli et al. [22] 
mentioned that, HCQ may block hydrolysis of polypeptide 
product and HIV virus replication [22]. Further increasing 
endosomal pH changes the activity of hydrolases enzyme 
which inhibits glycoprotein production [22]. Wang et al., [23] 
found that, HCQ activates innate immune signal pathways 
and interferes mitochondrial viral signalling [23]. Further, 
HCQ induces production of cellular reactive oxygen which 
imparts in host defence system [23]. Pandya et al., [24] 
reported that, mechanism of HCQ action against 
Chikunguniya virus is still unclear; however, it is related to 
anti-inflammatory response. Chandramohan et al., [25] 
mentioned that, HCQ is responsible for blocking of 
endocytosis mechanism required for hepatitis C virus entry. 
Increase in lysosomal pH causes inactivation of lysosomal 
enzymes which prevent further viral replication. Dyall et al 
[26] and Yao et al., [27] proposed that, HCQ affects entry of 
virus, increases the pH of endosome. Further, it knocks down 
the endocytosis process and viral replication phenomenon in 
corona viruses. Thus HCQ plays an important role against 
various viral infections and hence similar kind of mechanistic 
role may be expected in case of action of HCQ against COVID-
19 virus which may needs strong evidences to prove it. 
3. Effects of HCQ on the immune system and 
COVID-19: 
In case of COVID-19, the lung injury is more obvious in 
critical patients that are directly linked with a cytokine storm. 
The pro-inflammatory cytokine storm with a severe illness 
affected the prognosis. Various IL-6 antibody blockers, 
convalescent plasma therapies have been applied to offset the 
cytokine storm. Hence it is predicted that, HCQ may be used 
against COVID-19, considering its antiviral [20-27] and 
immunimodulatory effects [11-13]. The excessive productions 
of cytokines lead to obstruct innate immune response [11-
13]. The HCQ regulates or modulates the production of 
different cytokines (like IL-6, IL-1, IL-2) which are involved in 
the cytokine storm [11]. The HCQ also displayed anti-viral 
activity by stimulating the pathway of IFN-β via 
phosphorylation [11,12]. Further, HCQ endorse post-
translational adaptation of signalling proteins to modulate 
innate immune responses and thus it is postulated that, 
antiviral and immuno-modulatory effects of HCQ may 
synergetically combat the COVID-19 infection [11,12,28].. 
Besides this, HCQ considerably induces cellular production of 
reactive oxygen radical/species, which shows a significant 
role in host defence mechanism [11,28]. Thus, it is possible 
that, HCQ may be displaying an emerging role in regulating 
and alleviating the host innate immunity against COVID-19, 
however it requires further investigation to confirm the 
actual role of HCQ against COVID-19 considering innate 
immunity factor [11,12,28].  
4. In vitro inhibition of SARS-CoV-2 by HCQ and CQ 
Recently some reports are available which demonstrated in-
vitro [27,29] (Table 1, entries 1-8) and in-vivo [5-10] 
inhibition of SARS-CoV-2 virus by use of HCQ. Liu et al., [29] 
have studied antiviral effects of HCQ and CQ against the 
SARS-CoV-2 virus infection at various multiplicities of 
infection (MOI). They measured in vitro cytotoxicity of HCQ 
and CQ in African monkey kidney Vero-E6-cells [29]. They 
reported 249 and 273 µM CC50 (50% cytotoxic 
concentration) values for HCQ and CQ respectively (Table 1, 
entries 1,2). Further, EC50 (50 % effective maximal 
concentration) values was found to be slightly higher for 
HCQ than CQ which indicating lesser potency of HCQ over CQ 
(Table 1, entries 1-4) [29]. Considering the SI (selectivity 
index), CQ is found to be more potent than HCQ (Table 1, 
entry 1-4). However, author proposed the use of HCQ 
considering the safety and toxicity concern. In context to this, 
Yao et al., [27] have reported lesser EC50 value for HCQ (6.14 
and 0.72 µM) than CQ (23.9 and 5.47 µM) at 24 and 48 hours 
respectively which indicating that HCQ may be a more potent 
and safer drug than CQ to treat COVID-19 by considering in-
vitro antiviral activity (Table 1, entry 5-8).  
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Table 1: In vitro inhibition of SARS-CoV-2 virus by hydroxychloroquine and chloroquine 
Entry Drug EC50 CC50 SI IC50 Time Ref. 
1.   Chloroquine (0.01 MOI) 2.71 273 100.81 NM 48 h 29 
2.   Hydroxychloroquine (0.01 MOI) 4.51 249 55.32 NM 48 h 29 
3.   Chloroquine (0.02 MOI) 3.81 273 71.71 NM 48 h 29 
4.   Hydroxychloroquine  (0.02 MOI) 4.06 249 61.45 NM 48 h 29 
5.   Hydroxychloroquine 6.14 NM NM NM 24 h 27 
6.   Hydroxychloroquine 0.72 NM NM NM 48 h 27 
7.   Chloroquine 23.9 NM NM NM 24 h 27 
8.   Chloroquine 5.47 NM NM NM 48 h 27 
Unit for EC50 and CC50: µM 
Liu et al., [29] have confirmed these in vitro antiviral activity 
results by immunofluorescence microscopy analysis study 
which suggested that, HCQ and CQ causes blocking of 
transport of SARS-CoV-2 virus and its genome from co-
localization with early endosomes. Further, they assumed 
blocking of the endocytosis phenomenon due to endosome 
maturation attributed to change in endosome pH [29]. Thus 
both authors [27,29], concluded HCQ as a safer and less toxic 
drug to treat COVID-19 on the basis of in vitro analysis study. 
5. HCQ: Possible mechanism of action against 
COVID-19: 
Possible mechanism is proposed on the basis of initial 
assessment of HCQ as a drug against SARS-CoV-2 virus 
[27,29]. It is postulated that, HCQ functions in three different 
ways against the SARS-CoV-2 virus [29-33]. Angiotensin-
converting enzyme-2 (ACE-2) which was considered as a 
possible binding receptor for SARS-CoV is also known as a 
possible receptor for SARS-CoV-2 considering the amino acid 
homology [30]. It is recognized that, SARS-CoV-2 having 76 
% amino acid homology to that of SARS-CoV [2,3]. Thus it 
may be possible that, SARS-CoV-2 virus follows the similar 
kind of mechanism like SARS-CoV virus to enter into the 
host-cell [2,3]. SARS-CoV-2 has spike protein which involves 
the two subunits namely S1 and S2 [2,3,30]. The first S1-
subunit is showing binding ability towards receptor ACE-2 
(in adipose tissues); whereas, second S2-subunit is involving 
in membrane fusion and insertion of RNA into the cell 
[27,29,30]. Various mechanisms have been postulated in the 
literature about the antiviral action of HCQ which affects the 
viral entry pathway by decreasing the glycosylation of ACE-2 
[27,29,30]. Since, it is assumed that virus binds to ACE-2 
receptor to enter inside the host cell.  
HCQ is a weak base which can be accumulated within acidic 
organelles (endosome, Golgi vesicles and lysosomes) 
wherein actual pH is found to be low. After accumulation, the 
HCQ leads to affect acidic organelles as well as functioning of 
several acid hydrolase enzymes by increasing the pH of 
organelles [31]. Some viruses enter by endocytosis 
mechanism in which virus targets the lysosomes [31]. These 
lysosomes having low pH and by action of acid hydrolase 
enzymes viral particles are disrupted which liberates various 
viral contents (infections material, nucleic acid and enzymes) 
that required for viral replication [31]. The accumulated HCQ 
in acidic organelles has been found to hamper the process of 
endocytosis and subsequent virus replication by increasing 
the pH level of lysosomes. Thus, HCQ is assumed to affect the 
viral entry [31]. 
In some cases virus is transported to endosome and gets 
replicated in it [32]. These endosome are get ruptured by 
low pH acidic intracellular lysosome enzymes and leads to 
relive the viral contents and replicated virons [32]. It is 
believed that, accumulation of HCQ increases the pH level of 
endosome as well as Golgi network and interfere functioning 
of various important acid hydrolases enzymes that hamper 
synthesis of new protein modification and viral inside-
outside entry mechanism [32]. Thus in conclusion, these HCQ 
changes the pH of cell organelles and inhibit the fusion 
process of virons, replication, glycosylation of viral proteins, 
endocytosis, viron transport and viron release [27,29,30-32]. 
6. In vivo inhibition of SARS-CoV-2: 
Till date only 9 clinical trials/case study reports are available 
which indicating the use of HCQ in COVID-19. Some case 
studies are showing good outcome with the HCQ treatment 
while some case studies are reporting poor clinical outcome 
with substantial adverse effects. Chen et al. [5], reported 
open 1:1 controlled trial study in COVID-19 patients treated 
with the HCQ which indicated no significant effect of HCQ in 
treatment of COVID-19 patients compared to that of control 
group. 33.3 % patients from the HCQ group and 46.7 % 
patients from control group showed radiographic 
progression in follow-up examination (Table 2, entry 1). 
Throat swab for SARS-CoV-2 was found to be negative for 
86.7% and 93.3% cases of HCQ group and control group 
respectively. Thus, they did not observe any specific 
distinction in between HCQ treatment and conventional 
treatment for COVID-19. The major limitation of this study is 
the smaller sample size and lower statistical significance.  
A French group Gautret et al., [6] have reported effective use 
of hydroxychloroquine + azithromycin (HCQ + AZT) in 
treatment of COVID-19 which cured 100 % patients on sixth 
day whereas, 57 % patients were cured virologicaly by only 
HCQ treatment on sixth day (Table 2, entry 2). In comparison 
to this, 12.5% patients were cured virologicaly in control 
group on sixth day. The total duration of 
treatment/medication was ten days. In their report, no 
specific adverse effects (of use of HCQ +AZT) are mentioned 
except one death. This study has several limitations such as 
small sample size, limited follow-up, exclusion of patients 
during treatment and specific age group. However, another 
French group Molina et al., [7] reported no clinical benefit 
and poor clinical outcome with the synergetic treatment of 
AZT+HCQ in coronavirus disease-2019 patients (Table 2, 
entry 3). In their study, nasopharyngeal swab for SARS CoV-2 
virus were found to be positive in 80% patients on fifth day. 
The major limitation of this report is the absence of control 
study. Further, they have not reported details of study and 
statistical significance, since it is a letter to editor. 
Chen et al. [8], carried out 1:1 randomized clinical trials 
Badgujar et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2020; 10(3):304-311 
ISSN: 2250-1177                                                                                  [307]                                                                                 CODEN (USA): JDDTAO 
which indicating faster clinical recovery, pneumonia 
absorption and cough reduction in HCQ treated group as 
compared to control group (Table 2, entry 4). They showed 
improvement in pneumonia in 80.6% of HCQ treated 
patients compared to 54.8% of control group. Standard 
treatment involves use of oxygen therapy, immunoglobulin, 
antiviral use, antibacterial use with or without 
corticosteroids. They proposed that, HCQ acted as a 
protector for COVID-19 patient due to its antiviral and 
immunomodulatory effects. Two patients of HCQ treated 
group showed adverse effects, thus adverse effects needs to 
be address carefully in the HCQ treated patients. Further in 
another report of 80 mildly infected patients, Gautret et al. 
[9] have confirmed potential use of HCQ + AZT therapy for 
COVID-19 (Table 2, entry 5). In this study, they reported 
death of one patient, and in whole study they performed ECG 
in order to understand the detrimental side effects of HCQ + 
AZT. On fifth day, 97.5% of patients showed negative virus 
culture from respiratory sample, however, the major 
limitation of this study is the absence of control group.  
Notably, Chorin et al., [10] reported QT prolongation in 
number of patients due to treatment of HCQ and AZT in 
between 3-4 days. In this report, 30% of patients showed QT 
prolongation (> 40 ms), while 11% of patients showed QT 
increased (> 500 ms) which indicating the high risk 
arrhythmia (Table 2, entry 6). They reported death of four 
patients in a set of 84 patients. Tang et al., [33] mentioned 
use of HCQ against COVID-19 patients. They found that, 
medication of HCQ results in more alleviation of clinical 
symptoms than standard of care treatment (Table 2, entry 7). 
Specifically they mentioned that, viral response not increases 
but it accelerates the alleviation of clinical symptoms and 
recovery of lymphopenia. In final conclusion, no difference 
was observed in the main outcome of the HCQ group and 
control group. Mahevas et al. [34], carried out routine data 
analysis of 181 patients which concluded non-supportive use 
of HCQ for COVID-19 in their study compared to control 
group (Table 2, entry 8). Further, they found modification in 
ECG in 9.5% patent treated with HCQ. They reported death of 
2.8% and 4.6% patients in HCQ treated and control patient’s 
group respectively. Moreover, 28.6 % and 24.2 % patients 
from HCQ and control group showed development of acute 
respiratory distress syndrome. 
Magagnoli et al., [35] reported retrospective analysis of 368 
patients which are divided into three categories such as HCQ 
group, HCQ+AZT group and control group (Table 2, entry 9). 
They observed higher death ratio in HCQ treated group. They 
reported the rate of death as 27.8%, 22.1%, and 11.4%, in 
the HCQ, HCQ+AZT and control group respectively. Further 
they mentioned that, specific precaution is required for the 
use of HCQ which may show severe adverse effects. Thus the 
maximum number of recovery/discharge was from control 
group and not from HCQ treated group. 
Thus in conclusion, there are several dispute in use of HCQ 
for the treatment of COVID-19. Gautret et al., [6,9] and Chen 
et al., [8] supported the use of HCQ alone or in combination 
with antibiotic such as AZT. However, Chen et al., [5] Molina 
et al., [7] Mahaves et al., [34], Chorin et al., [10] and 
Magagnoli et al., [35] did not reported any significant 
effect/clinical outcome of HCQ treatment in their study of 
COVID-19 treatment. These findings (use of HCQ for COVID-
19) are not sufficient to conclude the use of HCQ for COVID-
19, thus important results and conclusion for the widespread 
adoption of HCQ against coronavirus disease-2019 are still 
awaiting. The individual uses of both these (HCQ and AZT) 
drugs are associated with QT Prolongation [33]. Hence QT 
prolongation is a major concern by synergetic use of HCQ + 
AZT in treatment of coronavirus disease-2019 [33]. Thus, 
there is an urgent need for the further reporting of case 
studies/clinical trials to get actual insights of clinical 
outcomes for possible use of HCQ against COVID-19 by 
considering an increasing widespread use of HCQ as a 
therapy as well as prophylaxis despite of its detrimental 
toxic effects. The major limitations of above mentioned 
studies is small sample size, random trials, short duration, 
limited follow-up, lack of control and no enrolment of 
children.
 
Table 2: Comparative account of literature review for the use of hydroxychloroquine in treatment of COVID-19 
St
u
d
y
 
Study design Treatment and dosage Control Observation and general 
conclusion 
Date 
publish/ 
Preprint 
Ref 
1 Open 1:1 controlled 
N = 30 
MA = 50.5 and 46.7 
TD: 5 days 
RN: NCT04261517 
15 patients: HCQ (400 mg 
per day for 5 days) + 
conventional treatments 
MA = 50.5  
15 patients: 
conventional 
treatment 
only 
MA = 46.7 
No major distinction between both 
groups. One patient from HCQ group 
becomes severe ill during the 
treatment.  
On seventh day, throat swab for SARS-
CoV-2 was found to be negative for 
86.7% and 93.3% cases of HCQ group 
and control group respectively.  
Transient diarrhea and abnormal liver 
function appeared in 26.7% of the 
HCQ group and 20% of the control 
group. 
Published  
03-Mar-20 
[5] 
2 Open-label non-
randomized clinical trial 
N = 36 
MA =45 
TD = 10 days 
RN: 2020-000890-25 
14 patients: HCQ 
(600mg/day for 10 days), MA 
=51.2 
On day six, 57.1% patients 
were  
virologicaly cured. 
6 patients: HCQ (600mg/day 
for 10 days) + AZT (500 mg 
on day one and then 250 mg 
per day upto fifth day),  MA 
16 patients: 
On day six, 
12.5% 
patients were  
virologicaly 
cured in the 
control 
 
Use of AZT along with HCQ showed 
more efficiency for elimination of 
virus load.  
Limitation: Major limitation is small 
sample size, limited follow-up, 
exclusion and specific age group of 
patients. 
 
Reported death of one patient 
Published  
20-Mar-20 
[6] 
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=37.3 
On day six, 100% patients 
were virologicaly cured. 
Any side effects are not reported. 
3 Observational study, 
non controlled 
N = 11 
MA = 58.7 
TD: 10 days 
11 patients: HCQ (600 
mg/day for 10 days)+ AZT  
(500 mg on day one and then 
250 mg per day upto fifth 
day) 
0 No indication of clinical benefit by 
HCQ + AZT treatment for severe 
COVID-19 patients. One patient died. 
The nasopharyngeal for SARS CoV-2 
were found to be positive for SARS-
CoV-2 in 80% patients on fifth day. 
Published  
30-Mar-20 
[7] 
4 Randomized clinical 
trial  
N = 62 
MA =44.7 
TD: 5 days 
RN:ChiCTR2000029559 
31 patients: 
Hydroxychloroquin (400 
mg/day for 5 days) + 
standard treatment 
MA =44.1 
 
31 patients: 
standard 
treatment only 
MA =45.2 
Reported clinical recovery, pneumonia 
absorption and cough reduction in 
HCQ treated group compared to 
control. 
Pre-print  
31-Mar-20 
[8] 
5 Uncontrolled non-
comparative 
observational study  
N = 80 
MA =53 
TD: 10 days 
2020 207 -000890-25 
80 patients: 
HCQ (600 mg per day for ten 
days) + AZT (500 mg on first 
days and then 250mg upto 
fifth day)  
0 On fifth day, 97.5% of patients showed 
negative virus cultures from 
respiratory sample. 
 
Reported death of one patient. 
Side effects of HCQ + AZT are 
determined by ECG study. 
Published  
11-Apr-20 
[9] 
6 Retrospective study 
N = 84 
MA =63 
84 patients: 
HCQ+AZT 
NR QT prolongation was observed in 
HCQ+AZT treated patients in between 
3-4 days. 30% of patients showed QT 
prolongation by greater than 40ms, 
while 11% of patients showed QT 
increased to >500 ms which 
indicating the high risk arrhythmia.  
Reported death of four patients. 
Pre-print 
03-Apr-20 
[10] 
7 Multicenter, open-label, 
randomized controlled 
trial 
N = 150 
N= 46.1 
DT: 2-3 weeks 
RNChiCTR2000029868 
 
75 patients: 
HCQ +SOC (1200 mg per day 
for 3 days and then 800 mg 
per day for 2-3 weeks) MA 
=48 
75 patients: 
standard of 
care only 
MA =44.1 
The medication of HCQ results in more 
alleviation of clinical symptoms than 
standard of care treatment. 
Adverse events were considerably 
increased in HCQ (30 %) recipients. 
No difference was observed in the 
main outcome of the HCQ group and 
control group. 
Pre-print  
14-Apr-20 
[33] 
8 Routine collected data 
N = 181 
MA =60 
TD: 7 days 
RN: 2020_060 
84 patients: HCQ (600 
mg/day for 2 days as only 
mentioned) + Standard care 
treatment 
97 patients: 
(No HCQ) 
Standard care 
treatment 
They mentioned that, clinical results 
did not support the HCQ use in 
COVID-19 patients. Further 
modification of ECG was observed in 
9.5% patients in HCQ treated group. 
They reported death of 2.8% and 4.6% 
patients in HCQ treated and control 
patients respectively. 
28.6 % and 24.2 % patients from HCQ 
and control group showed 
development of acute respiratory 
distress syndrome. 
Pre-print  
14-Apr-20 
[34] 
9 Retrospective analysis 
N = 368  
MA =69 
97 patients: (HCQ + standard 
supportive treatment),  
 
113 patients: (HCQ + AZT + 
standard supportive 
treatment) 
  
158 patients: 
standard 
supportive 
treatment only 
They reported the rates of death as 
27.8%, 22.1%, and 11.4%, in the HCQ, 
HCQ+AZT and control group 
respectively. Compared to control 
group, higher death ratio is observed 
in HCQ treated group. 
Rate of ventilation in HCQ, HCQ+AZT, 
and control groups were 13.3%, 6.9%, 
14.1%, respectively. Suggested caution 
in HCQ and AZT use in treatment. 
Pre-print  
21-Apr-20 
[35] 
N: No. of population (patients), MA: median age in population (years); TD: treatment days, 
RN: registration number 
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7. Prophylaxis use of HCQ 
Interestingly, HCQ is allowed to use as prophylaxis in order 
to prevent possible infection of COVID-19 [27,36,37]. Despite 
of several detrimental adverse effects and lack of evidences 
the question arises regarding to prophylactic use and dosage 
of the HCQ. Most recently, dosing study of HCQ is optimized 
by Yao et al. [27], who reported EC50 values (for HCQ) of 6.14 
and 0.72 μM at 24 and 48 hours respectively [27]. On the 
basis of physiologically-based pharmacokinetic models, 
dosing of 400 mg BID (on day 1) and 200 mg BID (from day 2 
to day 5) offers lung tissue trough concentration 21 and 83 
times higher than EC50 value at day 1 and day 10 respectively 
[27]. This study may indicated, effective use of HCQ as a 
prophylactic drug to prevent possible infection of COVID-19 
on the basis of model and in-vitro analysis [27]. Moreover, 
cytokine storm (in COVID-19 infection) may be regulated by 
immunomodulatory action of HCQ [11-13]. However, looking 
to contradictory case results of use of HCQ against COVID-19 
there is an urgent need for more confirmatory evidences [5-
10,33-35]. 
HCQ may looks a promising life saving drug for in-vitro 
inhibition of coronavirus, however in practise it failed to 
reduce the actual effective corona virus load in mice [38]. 
Thus it is not confirmatory that whatever works in-vitro can 
be work well in-vivo, hence there is an urgent need to study 
clinical trials [38-42]. Further sudden increased use of HCQ 
as a prophylaxis despite of strong effective evidences may 
faces detrimental side effects and leads to create shortage of 
HCQ drug [36-38]. More, recently some hospitals of France as 
well as Sweden have stopped use of HCQ/CQ in clinical case 
study/practice considering the lack of therapeutic evidences, 
detrimental side effects and poor clinical outcome [39,40]. It 
is mentioned by Ferari in media report Health-News that, use 
of HCQ +AZT sometimes may become more harmful than 
disease itself [39]. Moreover, recently, a death is reported by 
self-medicating use of CQ against COVID-19, hence, self-
medication as a prophylaxis should be avoided which may be 
harmful or some-times may be lethal [41,42]. Prophylaxis 
use of HCQ should be done after medical (practitioner) 
advice only. Thus at present, more confirmatory 
results/study reports are still awaited for prophylaxis use as 
well as in-vivo clinical use of HCQ to treat COVID-19 [36-42].  
8. Pharmacovigilliance approach for the use of 
HCQ: 
Literature showing several adverse events associated with 
the use of HCQ. Although HCQ is less toxic and safer than CQ, 
still it possesses some detrimental adverse effects which are 
not negligible and cannot be ignored. In view of 
pharmacovigilance concern, unnecessary and excess use of 
the HCQ (without physician advise) may be dangerous which 
may have several side effects (Table 3, entries 1-6) such as 
cardiac complications (Table 3, entry 1) [43], ocular side 
effects (Table 3, entry 2) [44], myopathy, neuropsychiatric 
effects (Table 3, entry 3) [45], gastrointenstinal  discomfort 
(Table 3 entry 4) [46], erythema multiforme, exanthematic 
pustulosis (Table 3, entry 5) [47], hypoglycaemia (Table 3, 
entry 6) [48], Stevens-Johnson syndrome (Table 3, entry 5) 
[49], thrombocytopenia (Table 3, entry 6) [17] and other 
common side effects such as weight-loss, appetite-loss, 
dizziness, weakness, nausea, vomiting and allergic reactions 
etc. (Table 3, entry 6) [50]. Most of these side effects are 
associated with the long term use. 
  
 
Table 3: Adverse effects of HCQ  
Entry Adverse effects Ref. 
1 Cardiac complications: QT prolongation, ventricular hypertrophy, ventricular arrhythmias, 
hypokinesia, cardiac arrest, pulmonary arterial hypertension, ventricular arrhythmias, valvular 
dysfunction, heart failure. 
[43] 
2 Ocular side effects: Retinopathy, blurred vision, blindness, corneal deposition [44] 
3 Neuro/muscular side effects: Signal conduction disorders, convulsion, myopathy, vertigo, 
psychrosis, ataxia, nightmare, depression 
[45] 
4 Gastrointestinal side effects: Diarrhoea, vomiting, abdomen cramping, nausea, abnormal liver 
function 
[46] 
5 Cutaneous/allergic side effects: Erythema multiforme, exanthematic pustulosis, Stevens–Johnson 
syndrome, allergy, rashes.  
[47,49] 
6 General major side effects: Thrombocytopenia, hypoglycaemia, obnubilation, weight loss, appetite 
loss. 
[48,50] 
 
 
Conclusion: 
In conclusion, HCQ shows antiviral effects against various 
viruses, further it’s use showed immunomodulatory effect. 
HCQ may be safe to use and required in lower dosage than 
CQ to inhibit viral load, to regulate cytokine storm and time-
span of viremia on the basis of in-vitro analysis. However, 
more clinical trials/ evidences are still awaited and required 
to prove in-vivo efficacy of HCQ against COVID-19. At 
present, clinical trials and case studies reported for the use 
of HCQ to combat COVID-19 showed the contradictory 
clinical outcome/results. QT prolongation is the major 
concern when HCQ is combined with drugs which tackle 
lower respiratory tract infection (e.g. AZT). Adverse effects 
cannot be neglected in use of HCQ against COVID-19. Thus 
the use of HCQ (in COVID-19 treatment) is of current 
international interest, although a consensus has not yet been 
reached. Extreme care is required for the HCQ treatment in 
pregnant women, pediatric patient and patient with 
comorbidity in coronavirus disease COVID-19. Misuse of HCQ 
as a prophylaxis of COVID-19 (without physician’s advise) 
should be avoided due to lack of strong evidences which may 
results into one or more detrimental side effects. Use of HCQ 
should be done after medical advice only. Considering 
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pharmacovigilance and public health concern, NO self 
medication of HCQ is advisable under any circumstances 
which may be risky and sometimes lethal. Thus the present 
review discussed the possible anti-viral mechanism of HCQ, 
prophylaxis strategy and effect of HCQ against SARS-CoV-2 
virus in-vitro study. Further this review also summarizes and 
debates all available clinical trials/ case studies of HCQ use 
against COVID-19 (with clinical outcome). Finally possible 
detrimental adverse effects are also discussed considering 
the public health and pharmacovigilance concern. 
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